In the wake of unprecedented workforce cuts at the FDA, former Commissioner Scott Gottlieb and an unnamed former CBER ...

Mass firings at the FDA have decimated divisions tasked with releasing public records generated by the agency's regulatory ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

As the Trump administration cuts thousands of federal jobs, some fired workers worry about health agencies' ability to ...

Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...

The Food and Drug Administration is reversing course on its requirement for all staffers to report to the office ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

The FDA was scheduled to release its decision on Novavax’s updated, protein-based COVID-19 vaccine on April 1, but the agency ...

A top federal health official ousted by the Trump administration denounced Health and Human Services Secretary Robert F.

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.